U.S. markets closed
  • S&P Futures

    4,218.75
    +5.00 (+0.12%)
     
  • Dow Futures

    33,790.00
    +29.00 (+0.09%)
     
  • Nasdaq Futures

    14,143.25
    +13.25 (+0.09%)
     
  • Russell 2000 Futures

    2,281.30
    +0.40 (+0.02%)
     
  • Crude Oil

    73.60
    -0.06 (-0.08%)
     
  • Gold

    1,785.50
    +2.60 (+0.15%)
     
  • Silver

    25.96
    -0.07 (-0.25%)
     
  • EUR/USD

    1.1910
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.4840
    +0.0340 (+2.34%)
     
  • Vix

    17.89
    -2.81 (-13.57%)
     
  • GBP/USD

    1.3914
    -0.0019 (-0.13%)
     
  • USD/JPY

    110.4010
    +0.1030 (+0.09%)
     
  • BTC-USD

    32,487.20
    -2,894.80 (-8.18%)
     
  • CMC Crypto 200

    780.78
    -69.57 (-8.18%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,731.30
    +720.37 (+2.57%)
     

Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, ON and BOSTON, May 27, 2021 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:00am EDT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

(PRNewsfoto/Fusion Pharmaceuticals Inc.)
(PRNewsfoto/Fusion Pharmaceuticals Inc.)

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform which includes internal research and development capabilities, manufacturing and supply chain expertise, and the Company's proprietary Fast-Clear™ linker technology.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-301301052.html

SOURCE Fusion Pharmaceuticals Inc.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2021/27/c7956.html